Loading...
Loading...
Shares of
Kite Pharma IncKITE were trading lower by more than 6 percent Monday morning after the clinical-stage bio-pharmaceutical company
confirmed that its facilities are undergoing a voluntary review.
Kite Pharma said its cell therapy manufacturing facilities at the National Cancer Institute (NCI) are undoing a voluntary internal review by the National Institutes Of Health (NIH). The company added this is connection with the NIH's review of all NCI facilities involving sterile material.
Kite Pharma further noted the review is not related to its lead product candidate, KTE-C19 or its overall manufacturing capabilities. In fact, the company confirmed that four ongoing multi-center clinical trials of its lead product continues and that it remains on track to file an investigational new drug application by the end of the year.
The stock traded recently at $47.12.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsMoversBio Pharmaceutical CompaniesCancer StocksKite PharmaKTE-C19National Cancer Institute
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
